Cutaneous T-cell lymphoma
Drug research and approvals for cutaneous T-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 60 studies of cutaneous T-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 7 approved and 18 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 60
- Trials authorized in Canada: 3
- FDA orphan approvals: 7
- EU medicines: 2
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaNCT07754890 · Phase 1 / Phase 2 · Peking Union Medical College Hospital · starts Aug 26, 2025
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaNCT07691450 · Phase 1 · City of Hope Medical Center · starts Jan 3, 2027
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaNCT07356245 · Phase 2 · Ohio State University Comprehensive Cancer Center · starts Feb 12, 2026
- Amping up With PemJAKNCT07283822 · Phase 2 · Seda S. Tolu · starts Dec 3, 2025
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesNCT07195916 · Phase 1 · Incyte Corporation · starts Jan 8, 2026
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaNCT07192471 · Phase 1 · Kyowa Kirin, Inc. · starts Sep 2, 2026
- Local Registry of Primary Cutaneous T-cell LymphomasNCT07160023 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Oct 12, 2023
- Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceNCT07132567 · Not reported · Kyowa Kirin Co., Ltd. · starts May 2, 2025
- Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)NCT07047885 · Phase 1 · H. Lee Moffitt Cancer Center and Research Institute · starts Aug 27, 2025
Approved 10
- RomidepsinHistone deacetylase inhibitor
- MechlorethamineMycosis fungoides · DNA inhibitor
- MogamulizumabMycosis fungoides · C-C chemokine receptor type 4 cross-linking agent
- BexaroteneRetinoid X receptor agonist
- MethotrexateMycosis fungoides · Dihydrofolate reductase inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- Denileukin diftitoxElongation factor 2 inhibitor
- PrednisoneMycosis fungoides · Glucocorticoid receptor agonist
- Dexamethasone phosphoric acidMycosis fungoides · Glucocorticoid receptor agonist
- DexamethasoneMycosis fungoides · Glucocorticoid receptor agonist
Phase 3 5
- Brentuximab vedotinMycosis fungoides · Tubulin inhibitor
- HypericinMycosis fungoides
- MethoxsalenMycosis fungoides · DNA inhibitor
- NaloxoneSezary syndrome · Opioid receptors; mu/kappa/delta antagonist
- ZanolimumabSezary syndrome · T-cell surface antigen CD4 other
Phase 2 12 of 31
- PembrolizumabMycosis fungoides · Programmed cell death protein 1 inhibitor
- PanobinostatHistone deacetylase inhibitor
- AlemtuzumabSezary syndrome · CAMPATH-1 antigen inhibitor
- Mycophenolate mofetilSezary syndrome · Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusSezary syndrome · FK506-binding protein 1A inhibitor
- BelinostatHistone deacetylase inhibitor
- ResiquimodToll-like receptor 8 agonist
- ResimmuneMycosis fungoides · Elongation factor 2 inhibitor
- Edodekin alfaSezary syndrome
- ResminostatSezary syndrome
- DoxycyclineSezary syndrome · Matrix metalloproteinase 7 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
Phase 1 or earlier 12 of 48
- FludarabineSezary syndrome
- PralatrexateDihydrofolate reductase inhibitor
- CarmustineGlutathione reductase inhibitor
- CarfilzomibMycosis fungoides · 26S proteasome inhibitor
- NivolumabMycosis fungoides · Programmed cell death protein 1 inhibitor
- AgatolimodMycosis fungoides · Toll-like receptor 9 agonist
- TanespimycinSezary syndrome · Heat shock protein HSP90 inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- Guanine
- 6-O-benzylguanine
- CyclosporineSezary syndrome · Cyclophilin A modulator
- DoxorubicinDNA topoisomerase II alpha inhibitor
How its trials ended
311 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 103 whose ending is known, 29% met their primary endpoint, 2% missed it and 69% stopped early.
- Completed, result not reported12741%
- Ongoing6320%
- Stopped: other or unclear3210%
- Met its primary endpoint3010%
- Stopped: enrollment or feasibility237%
- Status unknown186%
- Stopped: sponsor or business decision83%
- Stopped: funding41%
- Missed its primary endpoint21%
- Stopped: lack of efficacy21%
- Stopped: safety21%
| Nov 18, 2022 | An interventional, single-arm, open-label phase II study investigating the efficacy and safety of ANTI-PD1 immunotherapy for the treatment of patients with…Libtayo (cemiplimab) | Alberta Health Services, Cross Cancer Institute | Pending |
| Feb 6, 2019 | An open-label, multi-center extension study to investigate the efficacy and safety of cobomarsen (MRG-106) following systemic treatment, in subjects with ctcl,…Cobomarsen / Fludeoxyglucose 18F | Miragen Therapeutics | Pending |
| Aug 1, 2018 | Solar: a phase 2, randomized, open-label, parallel-group, active comparator, multi-center study to investigate the efficacy and safety of cobomarsen (MRG-106)…Cobomarsen | Miragen Therapeutics | Ongoing |
| Aug 7, 2024 | LymphirTreatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic… | Citius Oncology, Inc. | Approved |
| Aug 8, 2018 | PoteligeoPOTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after… | Kyowa Kirin Pharmaceutical Development Inc. | Approved |
| Aug 23, 2013 | ValchlorTopical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed… | Helsinn Birex Pharmaceuticals Ltd. | Approved |
| Nov 5, 2009 | IstodaxTreatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy | Celgene Corporation | Approved |
| Oct 6, 2006 | ZolinzaTreatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent… | Merck & Co., Inc. | Approved |
| Dec 29, 1999 | TargretinTreatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. | Eisai, Inc. | Approved |
| Feb 5, 1999 | OntakTreatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2… | Eisai, Inc. | Approved |
| Sep 22, 2023 | Resminostat mesilateTreatment of Cutaneous T-Cell Lymphoma (CTCL) | 4SC AG | Designated |
| Sep 14, 2022 | A ligand binding moiety to STAT3, a chemical linker, and a…Treatment of Cutaneous T-Cell Lymphoma (CTCL) | Kymera Therapeutics | Designated |
| Apr 4, 2018 | TenalisibTreatment of Cutaneous T-Cell Lymphoma | Rhizen Pharmaceuticals SA | Designated |
| Dec 19, 2017 | FenretinideTreatment of cutaneous T-cell lymphoma | SciTech Development, LLC | Designated |
| Jun 14, 2017 | LacutamabTreatment of cutaneous T-cell lymphoma. | Innate Pharma | Designated |
| May 24, 2017 | ResiquimodTreatment of cutaneous T-cell lymphoma | Galderma Research and Development, LLC | Designated |
| Feb 6, 2017 | Brentuximab vedotinTreatment of cutaneous T-cell lymphoma | Seagen Inc. | Designated |
| Oct 12, 2016 | Liposomal vinorelbineTreatment of cutaneous t-cell lymphoma (CTCL) | Taiwan Liposome Company, Ltd. | Designated |
| Mar 3, 2017 | LedagaChlormethine · orphan | Helsinn Birex Pharmaceuticals Ltd. | EMA ↗ |
| Mar 29, 2001 | TargretinBexarotene | H.A.C. Pharma | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA